EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
Mathurin Fumery 1
Antoine Defrance 2
Xavier Roblin 3
Carmen Stefanescu 4
Bénédicte Caron 5
Xavier Hebuterne 6
Romain Altwegg 7
Catherine Leberre 8
Maria Nachury 9
Antoine Meyer 10
Philippe Ah Soune 11
Cyrielle Gilletta De Saint Joseph 12
Nicolas DUVEAU 13
Mathieu Uzzan 14
Amelie Biron 15
David Laharie 16
Stephane NANCEY 17
My-Linh Tran-Minh 18
Ludovic Caillo 19
Thierry Paupard 20
Yasmine Elgharabawy 20
Laurent Peyrin-Biroulet 21
1 Amiens University Hospital, Amiens, France
2 GETAID, Paris, France
3 University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, France
4 Hopital Beaujon, Clichy, France
5 CHU Nancy, Nancy, France
6 Hospital Archet 2, Nice, Nice, France
7 Hopital Saint Eloi Hepatologie Gastro Enterologie, Montpellier, France
8 CHU Nantes, Nantes, France
9 CHRU Lille, Courbevoie Cedex, France
10 Hôpital Bicêtre, Bicetre, France
11 CH Toulon, Toulon, France
12 Hopital Rangueil, Toulouse, France
13 CH Roubaix, Roubaix Cedex 1, France
14 Hôpital Mondor, Paris, France
15 CHU Reims, Reims, France
16 CHU de Bordeaux, Pessac cedex, France
17 CHU Lyon, Pierre Benite, France
18 Hopital Saint-Louis, Paris, France
19 CHU de Nimes, Nîmes, France
20 CH Dunkerque, Dunkerque, France
21 Nancy University Hospital, Vandoeuvre-les-Nancy, France
Session
IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]